Skip to content
    Epidarex Capital logo

    Epidarex Capital

    Edinburgh, United KingdomFounded 2010
    epidarex.comLinkedIn
    Biotech & Life SciencesHealthcare

    Epidarex Capital is a transatlantic venture capital firm that invests in early-stage, high-growth life science and health technology companies in under-ventured research hubs across the UK and US. The firm focuses on company creation, often sourcing and building therapeutics and medical device companies from scratch.

    63% of their portfolio is in Biotech & Life Sciences. They made 2 investments in the last 12 months. Their most common stage is series-a (46% of deals). Average disclosed round size is $26.1M (across 17 rounds with reported amounts).

    Find people at Epidarex Capital on Goldilocks AI

    Portfolio

    21

    Fund Size

    —

    Top Stage

    Series A

    Last 12 Mo

    2

    Team

    Kyparissia Sirinakis

    Kyparissia Sirinakis

    Founding Partner

    A. Sinclair Dunlop

    A. Sinclair Dunlop

    Managing Partner

    BH

    Bridget Harris

    Director of Operations

    MM

    Matthew Miessau

    Principal

    SM

    Sara McGeachy

    Investor Relations Analyst

    AM

    Alicia MacLeod

    Executive Assistant

    AP

    Andrew Prince

    Staff Accountant

    AV

    Anthony Voveris

    Chief Financial Officer

    CG

    Clare Gaffney

    Operations and Executive Assistant

    Portfolio Breakdown

    Stage Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    41 investments
    CompanyRoundAmountDate
    Mironid logoMironidSeries B$46MAug 2026
    RRapidPulse, Inc.Series B$48MJul 2026
    RRapidPulse, Inc.Series B$48MJan 2026
    Leucid Bio logoLeucid BioSeries A—Feb 2025
    Epsilogen Ltd logoEpsilogen LtdSeries B—Sep 2024
    Curve Therapeutics logoCurve TherapeuticsSeries A$40.5MFeb 2024
    Enterprise Therapeutics logoEnterprise TherapeuticsSeries B$26MJan 2024
    Epsilogen Ltd logoEpsilogen LtdSeries B—Jan 2024
    Mironid logoMironidSeries A—Sep 2023
    Transine Therapeutics logoTransine TherapeuticsSeed—May 2022
    Leucid Bio logoLeucid BioSeries A—Oct 2021
    Topas Therapeutics logoTopas TherapeuticsSeries B—Jul 2021
    Slate Bio, Inc. logoSlate Bio, Inc.Seed$1.8MJan 2021
    Leucid Bio logoLeucid BioSeries A—Jan 2021
    Libra Therapeutics logoLibra TherapeuticsSeries A$29MSep 2020
    NodThera logoNodTheraSeries B$55MJun 2020
    Epsilogen Ltd logoEpsilogen LtdSeries A—Apr 2020
    AAdoRx TherapeuticsUnknown$10MNov 2018
    NodThera logoNodTheraSeries A—Jun 2018
    AAdoRx TherapeuticsUnknown$10MJun 2018
    AAdoRx TherapeuticsUnknown$10MJan 2018
    NodThera logoNodTheraSeries A—Jan 2018
    Epsilogen Ltd logoEpsilogen LtdSeries A—Jun 2017
    Apellis logoApellisSeries E$60MJan 2017
    Enterprise Therapeutics logoEnterprise TherapeuticsSeries A—Dec 2016
    Page 1 of 2

    Top Co-Investors

    Sofinnova Partners8 shared
    British Business Bank6 shared
    British Patient Capital4 shared
    Novartis Venture Fund4 shared
    Versant Ventures4 shared
    F-Prime Capital4 shared
    Fidelity Investments4 shared
    AlbionVC3 shared
    GG13 shared
    Boehringer Ingelheim Venture Fund3 shared
    Scottish Enterprise Growth Investment Team3 shared
    Dementia Discovery Fund2 shared
    Takeda Ventures, Inc.2 shared
    3B Future Health Fund2 shared
    Roche Venture Fund2 shared
    BioGeneration Ventures2 shared
    Gimv2 shared
    Cormorant Asset Management2 shared
    AJU IB Investment2 shared
    Medtronic2 shared

    Last updated: 20 October 2026